Andrew W. Aw

Ottawa, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: February 20, 2025

Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.

Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.

Journal: Leukemia & lymphoma

Published: January 18, 2024

Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.

Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.

Journal: Leukemia research

Published: June 30, 2023

Corrigendum to "Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update" [Leukemia Research 125 (2023) 107016].

Corrigendum to "Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update" [Leukemia Research 125 (2023) 107016].

Journal: Leukemia research

Published: April 05, 2023

Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.

Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.

Journal: Current oncology (Toronto, Ont.)

Published: March 21, 2023

Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.

Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.

Journal: Leukemia research

Published: November 15, 2022

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial.

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial.

Journal: BMJ open

Published: July 21, 2022

Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario.

Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario.

Journal: Current oncology (Toronto, Ont.)

Published: October 08, 2021

To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report.

To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 04, 2021

Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.

Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.

Journal: Current oncology (Toronto, Ont.)

Published: December 31, 2020

First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma.

First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma.

Journal: Current oncology (Toronto, Ont.)

Published: December 31, 2020

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.

Journal: Current oncology (Toronto, Ont.)

Published: November 16, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026